The US-Australia FTA included a raft of provisions enhancing the transparency and accountability of PBS decision-making. The agreement led to company hearings before the Pharmaceutical Benefits Advisory Committee and the publication of Public Summary Documents.
Latest Video
New Stories
-
Medicines Australia seeks answers on AI in HTA process
September 23, 2026 - - Latest News -
The prevention gap and inside Sally Panton's bet on cellular health
September 23, 2026 - - Latest News -
Pfizer 'deeply disappointed' in response to PBAC refusing to move on price
September 23, 2026 - - Latest News -
Lilly goes direct with a patient platform for its non-PBS medicines
September 23, 2026 - - Latest News -
A 'multistakeholder' reference group to shadow agreement negotiations
September 23, 2026 - -
If there is a productivity gain in the process, then it should be passed on
September 22, 2026 - - Latest News -
Given the official use of AI, a cease and desist would not be unreasonable
September 22, 2026 - - Latest News
